{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:06:13Z","timestamp":1793160373271,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03328-y","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:27:17Z","timestamp":1756380437000},"page":"5215-5237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R.","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Suravaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Palac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Wegrzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"3328_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103410","volume":"22","author":"G Monteleone","year":"2023","unstructured":"Monteleone G, Moscardelli A, Colella A, Marafini I, Salvatori S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmun Rev. 2023;22:103410.","journal-title":"Autoimmun Rev"},{"key":"3328_CR2","doi-asserted-by":"crossref","unstructured":"Kraev K, Geneva-Popova MG, Hristov BK, et al. Examining the safety profile of Janus kinase (JAK) inhibitors in the management of immune-mediated diseases: a comprehensive review. Life (Basel). 2023;13:2244.","DOI":"10.3390\/life13122244"},{"key":"3328_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71\u201387.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"3328_CR5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"AR Balanescu","year":"2022","unstructured":"Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81:1491\u2013503.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u201329.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","volume":"82","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82:331\u201343.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2022-eular.1238","volume":"81","author":"G Karpouzas","year":"2022","unstructured":"Karpouzas G, Szekanecz Z, Baecklund E, et al. POS0519 Relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or TNF inhibitors: a post hoc analysis of ORAL Surveillance. Ann Rheum Dis. 2022;81:517\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82:901\u201310.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR10","unstructured":"RINVOQ (upadacitinib). Prescribing information. AbbVie Inc.; 2025. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 6 May\u00a02025."},{"key":"3328_CR11","unstructured":"A study to assess change in disease activity and adverse events of oral upadacitinib in adult and adolescent participants with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy (step-up HS). ClinicalTrials.gov identifier NCT05889182. https:\/\/clinicaltrials.gov\/study\/NCT05889182. Accessed 4 Mar 2025."},{"key":"3328_CR12","unstructured":"A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo (Viti-Up). ClinicalTrials.gov identifier NCT06118411. https:\/\/clinicaltrials.gov\/study\/NCT06118411. Accessed 4 Mar 2025."},{"key":"3328_CR13","unstructured":"A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe alopecia areata (Up-AA). ClinicalTrials.gov identifier NCT06012240. https:\/\/clinicaltrials.gov\/study\/NCT06012240. Accessed 4 Mar 2025."},{"key":"3328_CR14","unstructured":"Program to assess adverse events and change in disease activity of oral upadacitinib in adult participants with moderate to severe systemic lupus erythematosus (SELECT-SLE). ClinicalTrials.gov identifier NCT05843643. https:\/\/clinicaltrials.gov\/study\/NCT05843643. Accessed 4 Mar 2025."},{"key":"3328_CR15","unstructured":"A study to evaluate the efficacy and safety of upadacitinib in participants with takayasu arteritis (TAK) (SELECT-TAK). ClinicalTrials.gov identifier NCT04161898. https:\/\/clinicaltrials.gov\/study\/NCT04161898. Accessed 4 Mar 2025."},{"key":"3328_CR16","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9:e002735.","journal-title":"RMD Open"},{"key":"3328_CR17","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase\u00a03 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"3328_CR18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400:369\u201379.","journal-title":"Lancet"},{"key":"3328_CR19","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase\u00a0III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"3328_CR20","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase\u00a03 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"3328_CR21","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"key":"3328_CR22","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"3328_CR23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227\u201339.","journal-title":"N Engl J Med"},{"key":"3328_CR24","first-page":"312","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312\u201320.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR25","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2021;397:2169\u201381.","journal-title":"Lancet"},{"key":"3328_CR26","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"3328_CR27","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase\u00a03 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"3328_CR28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase\u00a03 trial. Ann Rheum Dis. 2022;81:1515\u201323.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR29","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS\u00a01): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a02\/3 trial. Lancet. 2019;394:2108\u201317.","journal-title":"Lancet"},{"key":"3328_CR30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"3328_CR31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","volume":"8","author":"S Vermeire","year":"2023","unstructured":"Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8\u00a0week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase\u00a03 maintenance study. Lancet Gastroenterol Hepatol. 2023;8:976\u201389.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3328_CR32","first-page":"1401","volume":"34","author":"T Woodworth","year":"2007","unstructured":"Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol. 2007;34:1401\u201314.","journal-title":"J Rheumatol"},{"key":"3328_CR33","doi-asserted-by":"crossref","first-page":"1759720X2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3328_CR34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.46497\/ArchRheumatol.2024.10645","volume":"39","author":"M Tada","year":"2024","unstructured":"Tada M, Okano T, Mamaoto K, et al. Comparison of creatine kinase elevation caused by Janus kinase inhibitors and interleukin-6 inhibitors in patients with rheumatoid arthritis: a propensity score-matched study. Arch Rheumatol. 2024;39:350\u20137.","journal-title":"Arch Rheumatol"},{"key":"3328_CR35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2024.03.027","volume":"91","author":"D Manzar","year":"2024","unstructured":"Manzar D, Suntres E, Nair N, Patel Y, Abu-Hilal M. Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: a systematic review and meta-analysis. J Am Acad Dermatol. 2024;91:168\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"3328_CR36","doi-asserted-by":"crossref","unstructured":"Falcon BTQ, de Mello Guimaraes T, Halpern GA, Gomes C, de Mello Guimaraes T. Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases\u2014a meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2025;44(2):154\u201362.","DOI":"10.1007\/s12664-024-01720-0"},{"key":"3328_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20:102776.","journal-title":"Autoimmun Rev"},{"key":"3328_CR38","volume":"214","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol. 2020;214:108397.","journal-title":"Clin Immunol"},{"key":"3328_CR39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MAJ.0b013e3182514059","volume":"343","author":"J Rosenbaum","year":"2012","unstructured":"Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci. 2012;343:364\u20136.","journal-title":"Am J Med Sci"},{"key":"3328_CR40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123:144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3328_CR41","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","volume":"40","author":"M Barreiro-de Acosta","year":"2023","unstructured":"Barreiro-de Acosta M, Molero A, Artime E, et al. Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn\u2019s disease) in Spain: a systematic review. Adv Ther. 2023;40:1975\u20132014.","journal-title":"Adv Ther"},{"key":"3328_CR42","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","volume":"58","author":"SS Zhao","year":"2019","unstructured":"Zhao SS, Ermann J, Xu C, et al. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology (Oxford). 2019;58:2025\u201330.","journal-title":"Rheumatology (Oxford)"},{"key":"3328_CR43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/ard-2023-224965","volume":"83","author":"S Exarchou","year":"2024","unstructured":"Exarchou S, Di Giuseppe D, Klingberg E, et al. Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study. Ann Rheum Dis. 2024;83:446\u201356.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR44","doi-asserted-by":"crossref","unstructured":"Taylor PC, Atzeni F, Balsa A, Gossec L, M\u00fcller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509.","DOI":"10.3390\/jcm10030509"},{"key":"3328_CR45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/derm.2022.0027","volume":"34","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Kircik L, Simpson E, et al. Pooled analysis of baricitinib tolerability in patients with atopic dermatitis in relation to acne, headache, and gastrointestinal events from 8 clinical trials. Dermatitis. 2023;34:308\u201314.","journal-title":"Dermatitis"},{"key":"3328_CR46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase\u00a0II and phase\u00a0III clinical trial program. Am J Clin Dermatol. 2021;22:693\u2013707.","journal-title":"Am J Clin Dermatol"},{"key":"3328_CR47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase\u00a03 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87:784\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"3328_CR48","unstructured":"US Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication\u2014FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 17 June 2024."},{"key":"3328_CR49","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi)\u2014referral. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Accessed 17 June 2024."},{"key":"3328_CR50","doi-asserted-by":"crossref","unstructured":"Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37\u2009066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595.","DOI":"10.1136\/rmdopen-2021-001595"},{"key":"3328_CR51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3\u00a0years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81:335\u201343.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6\u00a0years. Ann Rheum Dis. 2022;81:184\u201392.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR53","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/ard-2023-223916","volume":"82","author":"R Fleischmann","year":"2023","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase\u00a0III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023;82:1130\u201341.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR55","doi-asserted-by":"crossref","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9:e003392.","DOI":"10.1136\/rmdopen-2023-003392"},{"key":"3328_CR56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13:729\u201349.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3328_CR57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39\u201352.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2024-eular.763","volume":"83","author":"KL Winthrop","year":"2024","unstructured":"Winthrop KL, Penn SK, Klaff J, et al. OP0020 Immunogenicity of an adjuvant recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomized substudy. Ann Rheum Dis. 2024;83:80\u20131.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","volume":"11","author":"A Rubbert-Roth","year":"2024","unstructured":"Rubbert-Roth A, Kakehasi AM, Takeuchi T, et al. Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11:97\u2013112.","journal-title":"Rheumatol Ther"},{"key":"3328_CR60","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4\u00a0years of exposure. Am J Clin Dermatol. 2024;25:639\u201354.","journal-title":"Am J Clin Dermatol"},{"key":"3328_CR61","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard-2024-225759","volume":"83","author":"GR Burmester","year":"2024","unstructured":"Burmester GR, Gottenberg JE, Caporali R, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3\u00a0years. Ann Rheum Dis. 2024;83:1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3328_CR62","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","volume":"34","author":"N Khan","year":"2017","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging. 2017;34:859\u201368.","journal-title":"Drugs Aging"},{"key":"3328_CR63","doi-asserted-by":"crossref","unstructured":"Li Z, Wang Y, Wu Y, et al. Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single-center prospective study. Allergy. 2025;80(5):1417\u201327.","DOI":"10.1111\/all.16495"},{"key":"3328_CR64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ueg2.12704","volume":"12","author":"A Nogami","year":"2024","unstructured":"Nogami A, Asonuma K, Okabayashi S, et al. Real-world comparative effectiveness and safety of filgotinib and upadacitinib for ulcerative colitis: a multicentre cohort study. United Eur Gastroenterol J. 2024;12:1357\u201366.","journal-title":"United Eur Gastroenterol J"},{"key":"3328_CR65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40261-024-01382-y","volume":"44","author":"C Patruno","year":"2024","unstructured":"Patruno C, Lauletta G, Pezzolo E, et al. Effectiveness and safety of upadacitinib for adolescents with atopic dermatitis in a real-world setting. Clin Drug Investig. 2024;44:629\u201334.","journal-title":"Clin Drug Investig"},{"key":"3328_CR66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340.","journal-title":"Inflamm Bowel Dis"},{"key":"3328_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","volume":"23","author":"N Iwamoto","year":"2021","unstructured":"Iwamoto N, Sato S, Kurushima S, et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther. 2021;23:197.","journal-title":"Arthritis Res Ther"},{"key":"3328_CR68","unstructured":"XELJANZ (tofacitinib). Prescribing information. Pfizer Inc.; 2024. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed 21 May\u00a02025."},{"key":"3328_CR69","unstructured":"OLUMIANT (baricitinib). Prescribing information. Eli Lilly and Company; 2022. https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi. Accessed 21 May\u00a02025."},{"key":"3328_CR70","unstructured":"CIBINQO (abrocitinib). Prescribing information. Pfizer Inc; 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16652. Accessed 21 May\u00a02025."},{"key":"3328_CR71","unstructured":"JYSELECA (filgotinib). Summary of Product Characteristics. Alfasigma S.p.A.; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf. Accessed 6 May\u00a02024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03328-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:32Z","timestamp":1758899372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03328-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03328-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing support was provided by Jay Parekh, PharmD, ISMPP CMPP\u2122, of JB\u00a0Ashtin, and funded by AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}},{"value":"Gerd R Burmester reports consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Lilly, Pfizer, and Sanofi; and speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Chugai, Galapagos, Lilly, Pfizer, and Sanofi. Atul Deodhar has received speaker fees from Johnson & Johnson, Novartis, Pfizer, and UCB; consulting fees from Bristol Myers Squibb, Johnson & Johnson, Lilly, MoonLake, Novartis, Pfizer, and UCB; and grant\/research support from Bristol Myers Squibb, Johnson & Johnson, Lilly, MoonLake, Novartis, Pfizer, and UCB. Alan D Irvine has received grants, consulting fees, and\/or advisory board honoraria from AbbVie, Almirall, Arena, Benevolent AI, Connect Biopharma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, and UCB. He is on the board of directors of the International Eczema Council. Remo\u00a0Panaccione has received consulting fees from AbbVie, Abbott, Abbivax, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Fresenius Kabi, Galapagos, Inviva, Genentech, Gilead Sciences, GSK, JAMP Bio, Janssen, Lilly, Merck, Mirador, Novartis, Oppilan Pharma, Odyssey, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Satisfai Health, Shire, Spyre Therapeutics, Sublimity Therapeutics, Takeda, Teva, Tillots, Trellus, Union Biopharma, Viatris, Ventyx, and UCB; speaker fees from AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb, Celgene, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Lilly, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda; and has served on advisory boards for AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, GSK, JAMP Bio, Janssen, Lilly, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Sublimity Therapeutics, Takeda, and Ventyx. Kevin L Winthrop has received consulting fees, grants and\/or research support from AbbVie, AstraZeneca, Bristol Myers Squibb, Galapagos, Gilead, GSK, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB. Ruth Ann Vleugels is an investigator and\/or consultant for AbbVie, AstraZeneca, Lilly, Pfizer, and Priovant. Gweneth Levy, Smitha Suravaram, Hannah Palac, Lani Wegrzyn, Sharanya Ford, and Sebastian Meerwein are full-time employees of AbbVie, and may hold AbbVie stock and\/or stock options. Emma Guttman-Yassky is an employee of Mount Sinai and has received research grants (paid to the institution) from and\/or a consultant for AbbVie, Aclaris, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Apollo, Arcutis, Artax, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celldex, Centrexion, Concerto, Connect, Coty, DBV, Dualitas, Enveda, Escient, Galderma, Gate Bio, GSK, Incyte, Inmagene, Janssen, Jasper, Kymera, Kyowa Kirin, LEO Pharma, Lilly, Matchpoint, Merck, Nektar, NUMAB, Opsidio, OTSUKA, Pfizer, Pharmaxis, Proteologix, Q32 Bio, RAPT, RayThera, Regeneron, Ribon, Sanofi, SATO, Schr\u00f6dinger, Sitryx, Sun Pharma, Takeda, Teva, TRex, UCB, VRG Therapeutics, and Xencor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation guidelines, and applicable local regulations. An independent ethics committee or institutional review board at each study site approved the protocol. Patients (or legal guardians of adolescents) provided written informed consent before beginning the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}